Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration

Mirte M. Malingré(Meander Medisch Centrum), Jos H. Beijnen(The Netherlands Cancer Institute), Hilde Rosing(The Netherlands Cancer Institute), Franciska J. Koopman(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), W.W. ten Bokkel Huinink, Ken Duchin(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Jan H.M. Schellens(Utrecht University), Martha Swart(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Olaf van Tellingen(Dutch Cancer Society)
Anti-Cancer Drugs
November 1, 2000
10.1097/00001813-200011000-00004
Cited by 28

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884